Soligenix CTCL Therapy Clears Safety Review, Advances Toward 2026 Milestones
TL;DR
Soligenix's HyBryte therapy cleared a major safety milestone, positioning it ahead in the rare disease market with potential regulatory and commercial advantages.
The Data Monitoring Committee confirmed no safety issues in Soligenix's Phase 3 FLASH2 trial, which enrolls 80 CTCL patients and builds on prior Phase 3 data.
This safety milestone advances a novel therapy for cutaneous T-cell lymphoma, offering hope for patients with rare diseases and unmet medical needs.
Soligenix's HyBryte uses synthetic hypericin in a skin-directed approach for CTCL, marking an innovative step in biotechnology for rare cancers.
Found this article helpful?
Share it with your network and spread the knowledge!
The Data Monitoring Committee overseeing Soligenix Inc.'s confirmatory Phase 3 FLASH2 trial of HyBryte™ has reported no safety concerns to date, affirming the therapy's safety profile for treating early-stage cutaneous T-cell lymphoma. This milestone is significant because regulatory pathways for orphan diseases such as CTCL often hinge not only on efficacy, but on establishing a favorable safety profile.
Soligenix, a biopharmaceutical company focused on rare diseases and treatments with substantial unmet need, is developing HyBryte (synthetic hypericin) for early-stage CTCL and is now advancing toward critical milestones in 2026. The company announced that the DMC concluded there are no safety issues with the ongoing Phase 3 trial (https://ibn.fm/NGMxi).
The FLASH2 study builds on the earlier Phase 3 FLASH trial and will enroll approximately 80 subjects with early-stage CTCL, patch or plaque phase disease. For biotechnology companies working in rare diseases, reaching a safety milestone means one major hurdle is cleared and focus can shift more explicitly to efficacy and regulatory strategy.
Soligenix's announcement arrives amid mounting interest in HyBryte as a novel skin-directed therapy. The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX. This development underscores the advancing clinical trajectory of Soligenix's lead therapy and represents progress for patients with limited treatment options for this rare form of lymphoma.
Curated from InvestorBrandNetwork (IBN)
